Analysis of baseline laboratory characteristics of HIV-positive patients in Bulgaria treated with bictegravir /emtricitabine/ tenofovir anafelamide (early analysis)

• Príomhchruthaitheoirí: Dimitar Strashimirov (Údar), Ralitsa Yordanova (Údar), Rusina Grozdeva (Údar), Evgeni Penchev (Údar), Daniel Ivanov (Údar), Nina Yancheva-Petrova (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Annals of Antivirals and Antiretrovirals - Peertechz Publications, 2024-01-04.
• Ábhair: Research Article
• Rochtain ar líne: Connect to this object online.

<p>Introduction: Bictegravir/Emtricitabine/Tenofovir Anafelamide (B/F/TAF) is a recommended single tablet regimen with good tolerability and safety as well as durability of the virologic response. From its introduction in the country of Bulgaria in April 2021 till November 2021 it was given to...